Your Questions Answered About Coronavirus (COVID-19)

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

An FDA fast track designation was granted to DSP-5336, a novel treatment for patients with relapsed or refractory AML with KMT2A gene rearrangements.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.